Cline Christopher R.
Known title: Chief Financial OfficerCIK: 0001943192
Associated companies
Transaction History
| TVTX | ▲ Buy | Option Exercise | 20,000 | $349K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 27,473 | $1.7M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 20,735 | $1.3M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,900 | $121K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 400 | $26K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 642 | $43K | 9/2/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 310 | $14K | 5/6/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,181 | $102K | 5/5/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,014 | $43K | 4/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 9 | $370 | 4/14/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,239 | $304K | 4/14/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 65 | $2K | 4/13/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 110 | $4K | 2/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,635 | $53K | 2/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,242 | $233K | 2/3/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 28,130 | $0 | 1/31/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 20,000 | $325K | 12/1/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 20,000 | $700K | 12/1/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 119 | $2K | 9/4/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 454 | $8K | 9/3/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 470 | $8K | 8/27/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,784 | $38K | 5/5/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,920 | — | 5/2/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 48 | $631 | 4/11/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 5,192 | $104K | 2/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 21,500 | $0 | 1/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 865 | $16K | 1/22/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,490 | $29K | 9/9/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,750 | $0 | 9/5/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 514 | $5K | 9/4/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 54 | $364 | 4/11/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,818 | $33K | 2/1/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 25,000 | $0 | 1/31/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 853 | $8K | 1/23/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 457 | $7K | 9/5/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 455 | $8K | 5/10/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 47 | $1K | 4/11/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,588 | $35K | 2/1/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 20,250 | $0 | 1/31/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 852 | $19K | 1/24/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 5,000 | $0 | 9/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.